ArticleCommunications biology2025
PRICKLE3 protects VANGL proteins from CK1-mediated phosphorylation and RNF43-mediated degradation.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The PRICKLE proteins (PRICKLE1-PRICKLE4) play essential roles in the WNT/planar cell polarity (WNT/PCP) pathway in vertebrates. This signaling system governs cell polarity, tissue architecture, and coordinated cell movements, yet the specific roles and molecular mechanisms of individual PRICKLE members within this pathway are poorly understood. Here, we identify PRICKLE3 as a previously unrecognized, central regulator of WNT/PCP signaling in human cells, Xenopus laevis and zebrafish (Danio rerio) embryos. Using enhanced proximity biotinylation (miniTurboID) combined with mass spectrometry, we found PRICKLE3 enriched at the plasma membrane, where it associates with core WNT/PCP proteins, including VANGL1 and VANGL2. Through immunoblotting, live imaging and functional assays, we further demonstrated that PRICKLE3 selectively enhances VANGL1/2 stability by protecting them from Casein kinase 1ε (CK1ε)-mediated phosphorylation. Mechanistically, PRICKLE3 modulates an interaction network involving VANGL1/2, CK1ε, and the ubiquitin ligase RNF43, thereby increasing VANGL stabilization and accumulation at the plasma membrane. These effects were unique to PRICKLE3, as PRICKLE1 showed no comparable activity. Together, our findings reveal a PRICKLE3-specific mechanism that couples CK1ε inhibition with RNF43 suppression to stabilize VANGL complexes. We also provide a comprehensive interactome and molecular tools to support further functional dissection of the PRICKLE family in development and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.